SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced the first publication ...
SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the launch of the nCounter® ...
Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor DNA assay. Safety and activity of DCR-MYC, a first-in-class Dicer-substrate small interfering ...
Targeted therapies for cancer are increasingly being developed as an alternative for, and in addition to, immunotherapy. Altered tumor signaling can be exploited to single-out cancer cells for ...
Significance of the estrogen signaling pathway in EGFR wild-type lung adenocarcinoma. This is an ASCO Meeting Abstract from the 2014 ASCO Annual Meeting I. This abstract does not include a full text ...
SEATTLE, April 10, 2018 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced ...
Commercially available gene expression tests for predicting prostate cancer progression appear to be less accurate in black vs white men, according to a new study. Commercial gene expression tests ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results